- Home
- INZY vs IFRX Comparison
INZY vs IFRX Comparison
Compare INZY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- IFRX
- Stock Information
- Founded
- INZY 2015
- IFRX 2007
- Country
- INZY United States
- IFRX Germany
- Employees
- INZY N/A
- IFRX N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- INZY Health Care
- IFRX Health Care
- Exchange
- INZY Nasdaq
- IFRX Nasdaq
- Market Cap
- INZY 64.9M
- IFRX 65.8M
- IPO Year
- INZY 2020
- IFRX 2017
- Fundamental
- Price
- INZY $3.97
- IFRX $0.80
- Analyst Decision
- INZY Buy
- IFRX Strong Buy
- Analyst Count
- INZY 9
- IFRX 4
- Target Price
- INZY $15.22
- IFRX $7.75
- AVG Volume (30 Days)
- INZY 5.3M
- IFRX 730.3K
- Earning Date
- INZY 05-14-2025
- IFRX 05-07-2025
- Dividend Yield
- INZY N/A
- IFRX N/A
- EPS Growth
- INZY N/A
- IFRX N/A
- EPS
- INZY N/A
- IFRX N/A
- Revenue
- INZY N/A
- IFRX $140,242.00
- Revenue This Year
- INZY N/A
- IFRX $3.36
- Revenue Next Year
- INZY N/A
- IFRX $100.60
- P/E Ratio
- INZY N/A
- IFRX N/A
- Revenue Growth
- INZY N/A
- IFRX 30.90
- 52 Week Low
- INZY $0.72
- IFRX $0.71
- 52 Week High
- INZY $6.24
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- INZY 85.93
- IFRX 32.20
- Support Level
- INZY $3.94
- IFRX $0.71
- Resistance Level
- INZY $3.97
- IFRX $0.89
- Average True Range (ATR)
- INZY 0.08
- IFRX 0.14
- MACD
- INZY 0.12
- IFRX -0.13
- Stochastic Oscillator
- INZY 99.32
- IFRX 7.57
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.